A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-29
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.